Next Article in Journal
Characterization and Antioxidant Activity Determination of Neutral and Acidic Polysaccharides from Panax Ginseng C. A. Meyer
Previous Article in Journal
Synthesis and Antibacterial Activity of Difluoromethyl Cinnamoyl Amides
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 4
10.3390/molecules25040790
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis, and Antimicrobial Activities of 1,2,3-Triazole Glycoside Clickamers

by
Tamer El Malah
1,*,
Hany F. Nour
1,*,
Amira A. E. Satti
2,3,
Bahaa A. Hemdan
4,5 and
Wael A. El-Sayed
1,6
1
Photochemistry Department, Chemical Industries Research Division, National Research Centre, 33 El Buhouth Street, P.O. Box 12622 Cairo, Egypt
2
Chemistry Department, Faculty of Science and Arts in Qurayat, Jouf University, P.O. Box 77425 Qurayat, Saudi Arabia
3
Chemistry Department, College of Science, Sudan University of Science and Technology, P.O. Box 11116 Khartoum, Sudan
4
Water Pollution Research Department, Environmental Research Division, National Research Centre, 33 El Buhouth Street, P.O. Box 12622 Cairo, Egypt
5
Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, P.O. Box 781039 Assam, India
6
Department of Chemistry, College of Science, Qassim University, P.O. Box 51452 Buraidah, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(4), 790; https://doi.org/10.3390/molecules25040790
Submission received: 11 January 2020 / Revised: 8 February 2020 / Accepted: 10 February 2020 / Published: 12 February 2020
(This article belongs to the Section Bioorganic Chemistry)
Browse Figures
Versions Notes

Abstract

:
Bacterial resistance remains a significant threat and a leading cause of death worldwide, despite massive attempts to control infections. In an effort to develop biologically active antibacterial and antifungal agents, six novel aryl-substituted-1,2,3-triazoles linked to carbohydrate units were synthesized through the Cu(I)-catalyzed azide-alkyne cycloaddition CuAAC of substituted-arylazides with a selection of alkyne-functionalized sugars. The chemical structures of the new derivatives were verified using different spectroscopic techniques. The novel clicked 1,2,3-triazoles were evaluated for in vitro antibacterial activity against Gram-positive Staphylococcus aureus and Gram-negative Pseudomonas aeruginosa, and the obtained results were compared with the activity of the reference antibiotic “Ampicillin”. Likewise, in vitro antifungal activity of the new 1,2,3-triazoles was investigated against Candida albicans and Aspergillus niger using “Nystatin” as a reference drug. The results of the biological evaluation pointed out that Staphylococcus aureus was more susceptible to all of the tested compounds than other examined microbes. In addition, some tested compounds exhibited promising antifungal activity.

1. Introduction

Antimicrobial resistance has emerged as one of the most serious threats to global health. The evolution of bacterial resistance occurs through a wide variety of mechanisms, including acquisition of resistance genes via horizontal gene transfer and mutations [1,2,3,4]. Moreover, overuse and misuse of antibiotics without medical prescription accelerate the emergence and spread of multidrug- resistant bacteria [5,6,7]. Several bacterial strains have evolved sophisticated mechanisms, which allow them to survive and negate the onslaught of antibiotics. For instance, some isolated strains of Staphylococcus aureus have developed intrinsic resistance to many kinds of antibiotics, including β-lactams, glycopeptides, aminoglycosides, and fluoroquinolones [8,9,10,11]. Rifampicin was used as one of the most effective antibiotics for treatment of Mycobacterium tuberculosis through inhibition of the elongation of the messenger RNA. Bacterial resistance to Rifampicin was developed through genetic mutations, which significantly suppress its binding with β-subunit of the RNA polymerase [12,13,14]. Some species of Acinetobacter baumannii exhibited resistance to currently available antibiotics due to their ability to adapt and develop diverse strategies of resistance, including hydrolysis of β-lactam rings of antibiotics, reducing entry of antibiotics into target sites of bacteria, and alteration of bacterial targets by mutations [15,16]. Pseudomonas aeruginosa is characterized by its ability to exist in aggregates forming biofilms, which are highly resistant to antibiotics [17]. Therefore, special concern should be devoted to the development of new antimicrobial agents, possessing completely different chemical structures, and working with different modes of actions. The Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction offers a versatile synthetic access to the 1,2,3-triazole heterocycle derivatives, which are associated with a wide spectrum of pharmacological activities, including antimycobacterial [18,19,20,21], antitubercular [22,23,24,25], anticancer [26,27,28,29], antiviral [30,31,32,33,34], antidiabetic [35,36,37,38], antifungal [39,40,41,42], anti-HIV [43,44,45,46], anti-inflammatory [47,48,49,50], antimalarial [51,52,53,54], anti- oxidant [55,56,57,58], anti-proliferative [59,60,61,62] properties. The 1,2,3-triazole heterocycle has been utilized as a main component of many pharmaceutical drugs, such as carboxyamidotriazole (CAI) (I), cefatrizine (II), and tazobactum (III) (Figure 1). The synthesis of molecular architectures containing 1,2,3-triazole heterocycles via the CuAAC click approach offers many advantages, such as high stability, yielding, and chemoselectivity of products [63,64]. More importantly, click reactions are insensitive to oxygen or water and can be easily conducted under mild reaction conditions. 1,2,3-Triazoles linked to carbohydrates have attracted widespread attention, on account of their positive effect on enhancing solubility and biological activity [65,66,67,68,69,70,71]. In continuation of our previous work on the synthesis of bioactive molecular architectures based on the 1,2,3-triazole heterocycle [26,27,30], we report in this study the synthesis, characterization, and antimicrobial evaluation of six novel 1,2,3-triazole glycosides using the click chemistry synthetic approach.

2. Results and Discussion

2.1. Chemistry

Synthesis and Characterization

The Cu(I)-catalyzed cycloaddition of the 2-(2-(2-methoxyethoxy)ethoxy)-ethyl 3-azidobenzoate 1 [26] with the terminal alkyne groups of the acetylated D-galactose 2, D-glucose 3, and D-xylose 4 [72] afforded the corresponding 1,2,3-triazole-based glycosides 5–7 in good yields (75%–81%) as demonstrated in Scheme 1. The 1,2,3-triazole ring acts as a linker connecting the substituted-aryl and sugar units. Furthermore, it can offer an additional binding motif to biological targets through the basic nitrogen atoms. On the other side, the triethylene glycol units attached to the phenyl ring and the sugar parts provide dual functions, which include binding of biological targets through the electronegative oxygen atoms and enhancing the solubility of products. The chemical structures of the 1,2,3-triazole glucosides 5–7 were fully characterized using different spectroscopic techniques (Supporting Information, Figures S1–S6). The 1H NMR spectrum of compound 5, as an example, displayed three signals at δ 5.20–5.21, 8.10, and 8.90 ppm, corresponding to the anomeric CH of sugar, the single CH of triazole ring and the aromatic singlet signals, respectively. This clearly confirms connection of the aryl ring with the sugar part of compound 5 via the heterocyclic 1,2,3-triazole bridge. The 13C NMR spectrum of 5 showed the characteristic signals of the carboxylate functional groups attached to the molecule at δ 165.5–170.4 ppm, while the anomeric carbon appeared at δ 99.3 ppm. The FT-IR spectrum of 5 showed an absorption band at νmax 1749 cm−1 for the carboxylate C=O groups. The triethylene glycol units incorporated in the structural framework of 1,2,3-triazole glucosides 5–7, along with the acetate units of protected sugars 2–4, are expected to cooperatively contribute in binding of the bacterial targets as similar to the mode of action of Vancomycin antibiotic, which noncovalently binds to the d-Ala–d-Ala section of the bacterial cell wall precursors via hydrogen bonding interactions. In Scheme 2, the click reactions of the substituted aryl azide 8, which did not incorporate triethylene glycol units, with the alkyne functionalized sugars 2–4, yielded the corresponding 1,2,3-triazole glucosides 9–11.
The 1,2,3-triazole glycosides 9–11 were fully characterized using the various spectroscopic tools (Supporting Information, Figures S7–S12). The 1H NMR spectrum of the 1,2,3-triazole glycoside 9 showed a multiple signal at δ 5.16–5.21 ppm, corresponding to the anomeric CH proton of the sugar. It also displayed a characteristic singlet signal at δ 8.28 ppm for the 1,2,3-triazole CH. Two singlet signals appeared in the aromatic region at δ 7.62 and 7.74 ppm, referring to the singlet aromatic CH protons.
The appearance of these signals clearly confirms connection of the substituted aryl ring with the sugar unit of compound 9 through the heterocyclic 1,2,3-triazole bridge. The 13C NMR spectrum of 9 showed the C=O functional groups at δ 169.5–170.4 ppm, while the anomeric carbon appeared at δ 100.5 ppm. The FT-IR spectrum displayed the C=O absorption band at νmax 1749 cm−1.

2.2. Antimicrobial Activity

The antimicrobial properties of the novel 1,2,3-triazole glycosides 5–7 and 9–11 were evaluated towards four different microbial species; namely S. aureus, P. aeruginosa, C. albicans, and A. niger. The inhibition zone diameters of the tested compounds are shown in Table 1. The obtained results revealed that the most susceptible organism was S. aureus, which was found sensitive to all of the tested compounds.
Generally, compound 5 was the most potent among the series of the newly synthesized glyco- sides and showed distinctive antimicrobial activities. The largest size of the inhibition zone for S. aureus was recorded by compound 5 since the size was 21 ± 0.25 and 25 ± 0.15 mm using the disc and well diffusion assay, respectively. On the other side, the results revealed that compound 6 was the one possessing the least antimicrobial activity. Although the lowest inhibition zones were recorded for the two fungal species, it appeared to be moderately and highly sensitive to two of the tested compounds (Table 1). There is a significant zone of inhibition given by compound 5 against C. albicans and A. niger (15 and 14 mm) using the disc diffusion assay. From the obtained results, it can be concluded that the antimicrobial activities of compound 5 are better than the used reference drug towards S. aureus. Meanwhile, interestingly, this compound can eradicate all bacterial and fungal species, while the Ampicillin drug was able to kill bacterial species only and Nystatin drug had only high antifungal activity.
To establish the possible antimicrobial structure-activity relationship, the inactivation effects and the minimum inhibitory concentrations (MICs) values for all of the tested compounds were estimated against the four targeted microbial species. The obtained data through the MIC values revealed variability in the inhibitory concentrations of each compound against the targeted microbial species. From the results of the present study, it was established that the same concentration of several tested compounds could inhibit all microbial growth of all tested microorganisms during different time intervals. The MIC values of compound 5 were found to be 5 mg/mL within 10 for S. aureus and 15 min for P. aeruginosa, while for fungal species, C. albicans and A. niger, it was revealed to be 10 mg/mL at 10 min (Figure 2). In the case of compound 6, 10 mg/mL was capable of killing S. aureus and P. aeruginosa within 10 and 15 min, but this compound could not inactivate fungal species. Concerning the MIC values of compound 7, the results figured out the effective concentration of such derivative (10 mg/mL) that could inhibit the growth of S. aureus within 10 min and all other tested microbes within 15 min. The results displayed in Figure 3 clearly showed that the value of MIC of compound 9 was 10 mg/mL within 5 min for S. aureus, 10 min for P. aeruginosa, and 15 min for C. albicans and A. niger. The MIC values of compounds 10 and 11 against S. aureus, P. aeruginosa, C. albicans, and A. niger are 5 mg/mL at 5 min, 10 mg/mL at 10 min, and 10 mg/mL at 15 min (Figure 3). Accordingly, S. aureus was more susceptible to all of the tested compounds than other examined microbes, and compound 5 was found to be the most active compound.
In conclusion, the values of MIC using the standard broth dilution technique for all the tested compounds were documented and collected in Table 2. Although no definite structure–activity relationship could be determined based on the applied periods and effective concentrations, there are conclusions concerning structural differences that may influence the antimicrobial activity that can be concluded via correlation with certain characteristic structural features. Accordingly, the six-carbon sugar (galactopyranosyl) in the latter system resulted in higher activities than that containing the xylopyranosyl moiety. However, relatively low differences in activities were revealed by the compounds incorporating the dimethoxynitrophenyl-triazole structure system, which showed that the glycosides with gluco- and xylo- pyranosyl moieties were relatively higher than the triazole glycoside with the D-galactose sugar part. Furthermore, the differences in the observed activities of the glycosides 5 and 6 towards both prokaryotic and eukaryotic organisms revealed the importance of the conformation of the acetyl group at C-4 in the sugar moiety. The latter triazole glycosides have the same aromatic system, but possess the glucopyranosyl and galactopyranosyl epimers which differ only in the conformation of the acetyl group at C-4. Such activity correlation may account for a possible interaction of such group or even may influence the behavior of the sugar part which is also in agreement with the obtained results for similar structural systems [70].
On the other side, the triazole glycoside 5 with the galactopyranosyl moiety showed markedly higher activity than compound 9 which has the same sugar moiety, but both compounds differ in the attached substituted aryl system. This observation showed the effect of aryl substitution on the activity since the glycoside with (tetraoxadodecanoyl) phenyl system was highly active than its analogue dimethoxynitrophenyl-triazole. In addition, from the afforded results, it can be found that the growth inhibitory effects of compounds 10 and 11 were the same against all of the tested microbial strains.

2.2.1. Toxicity Evaluation of the Studied Compounds

The toxicity assay has been performed for safety verification of the designed compounds, and the results showed that all tested compounds were safe and had no hazardous effects for humankind. The readings of EC50% were 204%, 320%, 245%, 285%, and 195%, for compounds 5, 6, 7, 9, 10, and 11, respectively. The results also indicated that all EC50% values of all tested compounds were more than 100%, which means that such compounds are nontoxic. Moreover, the values EC50% of the reference drugs was also lower than 100% (Table 3).

2.2.2. The Kinetic Modeling of the Killing Rate of the Tested Microbes

From the kinetic modeling using pseudo-first-order, the results revealed that the rapidly inhibited strains were the S. aureus, while the lowest inhibition was observed for the fungal species. Moreover, the effective concentration of compound 5 was the one that could effectively inhibit the growth of all tested microbial strains within a shorter time than other compounds. It was interesting to note that the tested fungal species were damaged over a longer time (Table 4).

3. Experimental

3.1. Chemistry

3.1.1. General Procedures

All the reagents used for the reactions were purchased from Alfa Aesar Germany or Fisher (UK) and were used as obtained without further purification. The reactions were monitored by thin layer chromatography (TLC). TLC was performed on Macherey-Nagel aluminium-backed plates, pre-coated with silica gel 60 (UV254). Column chromatography was carried out on silica gel 60 (0.040–0.063 mm) under flash conditions. The 1H NMR and 13C NMR spectra were measured on a JEOL 400 MHz for 1H NMR and 100 MHz for 13C NMR in CDCl3, Microanalytical Center, Faculty of Pharmacy, Cairo University, Egypt. The chemical shifts (δ) were expressed in ppm relative to the standard TMS as an internal reference. The coupling constants (J) were given in Hz. The microanalytical data were carried out on a Vario El-Mentar instrument, Microanalytical Center, Cairo University, Egypt. The melting points were determined in open glass capillaries using an Electrothermal IA 9000 SERIES digital melting point apparatus (Electrothermal, UK) and are uncorrected. The FT-IR spectra were recorded on a Shimadzu IR 8400s spectrophotometer (KBr, νmax/cm−1) at the Micro Analytical Laboratory, Cairo University, Egypt. The aromatic azides (1 and 8) and acetylenic sugars (2, 3, and 4) were prepared according to the reported procedures in the literature [26,27,72].

3.1.2. General Click Chemistry Procedure

A three-necked flask was charged with alkynes compounds (2, 3, or 4) (1 equivalent), and aryl azides (1 or 8) (1 equivalent), sodium ascorbate (0.3 equivalent), TBTA (0.15 equivalent), and a solvent mixture of H2O/tBuOH/CH2Cl2 (1/2/8, 60 mL). The flask was evacuated and flushed with argon repeatedly (three cycles). CuSO4.5H2O was added (0.15 equivalent) and the mixture was stirred for two days at room temperature in the dark. After consumption of alkynes (2, 3, or 4) as indicated by TLC monitoring, the mixture was diluted with CH2Cl2 and transferred into a separating funnel. The organic phase was washed with an aqueous ethylenediaminetetraacetic acid (EDTA) disodium salt (EDTA-Na2) solution (3×), the aqueous phase was extracted with CH2Cl2 (3×), and aqueous saturated NaCl solution (1×) (60 mL volume). After drying over MgSO4, filtration, and removal of the solvent under vacuum the target compounds were obtained after purification by column chromatography.

3.1.3. (2R,3R,4S,5S,6R)-2-((1-(3-(2,5,8,11-tetraoxadodecanoyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(a-cetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (5)

The title compound was separated and purified by column chromatography (Petroleum ether/ethyl acetate 8/2) as a brown solid (81%). Mp 155–156 °C. TLC (Petroleum ether/ethyl acetate 8/2) Rf = 0.28. FT-IR (KBr, νmax/cm−1): 1749 (C=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 1.91, 1.94 (ss, 6 H, 2 COCH3), 2.03 (s, 3 H, COCH3), 2.13 (s, 3 H, COCH3), 3.37 (s, 3 H, OCH3), 3.62 (s, 3 H, CH2), 4.09–4.10 (m, 6 H, 3 CH2), 4.25–4.27 (ss, 3 H, CH+CH2), 4.76 (t, 3J = 8.51 Hz, 2 H, CH2), 4.87–5.19 (m, 6 H, 2 CH+2CH2), 5.20, 5.21 (m, 1 H, CH), 5.28 (s, 1 H, CH), 7.56 (s, 1 H, ArH), 7.69 (s, 1 H, ArH), 8.10 (s, 1 H, ArHtriazole), 8.41, 8.45 (ss, 1 H, ArH), 8.90 (s, 1 H, ArH). 13C NMR (75 MHz, CDCl3): δ (ppm) = 20.7 (COCH3), 20.8 (COCH3), 20.9 (COCH3), 53.1 (OCH3), 61.7 (CH2), 62.9 (CH2), 67.8 (CH2), 67.8 (CH2), 69.0 (CH), 70.4 (CH2), 70.6 (CH2), 71.2 (CH2), 71.7 (CH), 72.2 (CH2), 72.4 (CH), 73.4 (CH), 99.3 (CHOCsuger), 123.4 (CAr), 124.6 (CAr), 128.1 (CHtriazole), 128.5 (CAr), 129.2 (CAr), 136.7 (CAr), 140.5 (CAr), 144.1 (CtriazoleCH2O), 165.5, 169.5, 169.9, 170.4, 170.4 (C=O). Elemental analysis, calc. (%) for C31H41N3O15: C 53.52, H 5.94, N 6.04; found: C 53.74, H 6.17, N 5.86.

3.1.4. (2R,3R,4S,5R,6R)-2-((1-(3-(2,5,8,11-tetraoxadodecanoyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(a-cetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (6)

The title compound was separated and purified by column chromatography (Petroleum ether/ethyl acetate 8/2) as a yellow oil (78%). TLC (Petroleum ether/ethyl acetate 8/2) Rf = 0.30. FT-IR (KBr, νmax/cm−1): 1751 (C=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 1.93, 1.94 (ss, 6 H, 2 COCH3), 1.96 (s, 3 H, COCH3), 2.01 (s, 3 H, COCH3), 3.28 (s, 3 H, OCH3), 3.45-3.47 (m, 2 H, CH2), 3.56–3.73 (m, 6 H, 3 CH2), 3.79 (t, 3J = 4.76 Hz, 2 H, CH2), 4.09–4.13, 2 H, OCH2), 4.68, 4.70 (ss, 2 H, OCH2), 4.85, 4.88 (ss, 1 H, CH), 4.95–5.06 (m, 3 H, CH), 5.16 (m, 1 H, CH), 7.57 (t, 3J = 7.95 Hz, 1 H, ArH), 7.94 (d, 2J = 9.21 Hz, 1 H, ArH), 8.05 (s, 1 H, ArHtriazole), 8.07 (d, 2J = 7.83 Hz, 1 H, ArH), 8.31 (s, 1 H, ArH). 13C NMR (75 MHz, CDCl3): δ (ppm) = 20.5 (COCH3), 20.6 (COCH3), 20.7 (COCH3), 58.9 (OCH3), 61.8 (CH2), 62.7 (CH2), 64.6 (CH2), 68.3 (CH2), 69.0 (CH), 70.5 (CH2), 70.6 (CH2), 70.6 (CH2), 71.2 (CH), 71.8 (CH2), 72.0 (CH), 72.7 (CH), 100.0 (CHOCsuger), 121.2 (CAr), 121.3 (CAr), 124.8 (CHtriazole), 130.0 (CAr), 130.0 (CAr), 131.9 (CAr), 137.0 (CAr), 145.0 (CtriazoleCH2O), 165.1, 169.4, 169.4, 170.1, 170.6 (C=O). Elemental analysis, calc. (%) for C31H41N3O15: C 53.52, H 5.94, N 6.04; found: C 53.79, H 5.76, N 5.88.

3.1.5. (2R,3R,4S,5R)-2-((1-(3-(2,5,8,11-tetraoxadodecanoyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahyd-ro-2H-pyran-3,4,5-triyl triacetate (7)

The title compound was separated and purified by column chromatography (Petroleum ether/ethyl acetate 8/2) as a yellow oil (75%). TLC (Petroleum ether/ethyl acetate 8/2) Rf = 0.32. FT-IR (KBr, νmax/cm−1): 1749 (C=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 1.96 (s, 6 H, 2COCH3), 1.98 (s, 3 H, COCH3), 3.28 (s, 3 H, OCH3), 3.35–3.40 (m, 2 H, CH2), 3.44–3.47 (m, 2 H, CH2), 3.56–3.66 (m, 6 H, 3 CH2), 3.78–3.80 (m, 1 H, CHa), 4.08–4.12 (m, 1 H, CHb), 4.44–4.47 (m, 2 H, OCH2), 4.63, 4.65 (ss, 2 H, OCH2), 4.80–4.96 (m, 3 H, 2 CH), 5.12 (m, 1 H, CH), 7.56 (t, 3J = 5.28 Hz, 1 H, ArH), 7.96 (d, 2J = 8.10 Hz, 1 H, ArH), 8.03 (s, 1 H, ArHtriazole), 8.06 (d, 2J = 7.77 Hz, 1 H, ArH), 8.30 (s, 1 H, ArH). 13C NMR (75 MHz, CDCl3): δ (ppm) = 20.6 (COCH3), 20.7 (COCH3), 58.9 (OCH3), 62.1 (CH2), 62.2 (CH2), 64.6 (CH2), 68.7 (CH), 69.0 (CH2), 70.5 (CH), 70.5 (CH2), 70.6 (CH), 70.7 (CH2), 71.3 (CH2), 71.8 (CH2), 99.9 (CH2OCsuger), 121.1 (CAr), 121.2 (CAr), 124.8 (CHtriazole), 129.9 (CAr), 130.0 (CAr), 131.9 (CAr), 137.0 (CAr), 145.1 (CtriazoleCH2O), 169.1, 169.4, 169.8, 169.9 (C=O). Elemental analysis, calc. (%) for C28H37N3O13: C 53.93, H 5.98, N 6.74; found: C 53.68, H 6.21, N 6.57.

3.1.6. (2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-((1-(2,5-dimethoxy-4-nitrophenyl)-1H-1,2,3-triazol-4-yl)meth-oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (9)

The title compound was separated and purified by column chromatography (Petroleum ether/ethyl acetate 8/2) as a brown solid (77%). Mp 118–119 °C. TLC (Petroleum ether/ethyl acetate 8/2) Rf = 0.29. FT-IR (KBr, νmax/cm−1): 1749 (C=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 1.93 (s, 3 H, COCH3), 1.98, 199 (ss, 6 H, 2 COCH3), 2.09 (s, 3 H, COCH3), 3.62–3.66 (m, 1 H, CH), 3.92, 3.95 (ss, 6 H, 2 OCH3), 4.03–4.16 (m, 2 H, CHa+b), 4.64,4.66 (ss, 1 H, CH), 4.81, 4.84 (ss, 2 H, 2 CH), 4.96–5.02 (m, 2 H, CH2), 5.16–5.21 (m, 1 H, CH), 7.62 (s, 1 H, ArH), 7.74 (s, 1 H, ArH), 8.28 (s, 1 H, ArHtriazole). 13C NMR (75 MHz, CDCl3): δ (ppm) = 20.5 (COCH3), 20.6 (COCH3), 20.7 (COCH3), 20.7 (COCH3), 56.9 (OCH3), 57.3 (OCH3), 61.2 (CH2), 62.7 (CH2), 67.0 (CH), 68.8 (CH), 70.7 (CH), 70.8 (CH), 100.5 (CH2OCsuger), 110.1 (CAr), 110.4 (CAr), 125.0 (CHtriazole), 130.1 (CAr), 138.2 (CArNO2), 143.1 (CtriazoleCH2O), 144.4 (CArOCH3), 147.9 (CArOCH3), 169.5, 170.1, 170.2, 170. 4 (C=O). Elemental analysis, calc. (%) for C25H30N4O14: C 49.18, H 4.95, N 9.18; found: C 49.34, H 5.16, N 9.37.

3.1.7. (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-((1-(2,5-dimethoxy-4-nitrophenyl)-1H-1,2,3-triazol-4-yl)meth-oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (10)

The title compound was separated and purified by column chromatography (Petroleum ether/ethyl acetate 8/2) as a yellow solid (80%). Mp 145–146 °C. TLC (Petroleum ether/ethyl acetate 8/2) Rf = 0.33. FT-IR (KBr, νmax/cm−1): 1750 (C=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 1.93 (ss, 6 H, 2 COCH3), 1.96 (s, 3 H, COCH3), 2.02 (s, 3 H, COCH3), 3.92-3.95 (m, 1 H, CH), 4.08, 4.11 (ss, 6 H, 2 OCH3), 4.20–4.21 (m, 1 H, CHa), 4.21–4.23 (m, 1 H, CHb), 4.67, 4.69 (ss, 1 H, CH), 4.82, 4.85 (ss, 1 H, CH), 4.95–5.06 (m, 3 H, CH2+CH), 5.16 (m, 1 H, CH), 7.62 (s, 1 H, ArH), 7.74 (s, 1 H, ArH), 8.28 (s, 1 H, ArHtriazole). 13C NMR (75 MHz, CDCl3): δ (ppm) = 20.5 (COCH3), 20.6 (COCH3), 20.7 (COCH3), 20.7 (COCH3), 56.9 (OCH3), 57.3 (OCH3), 61.8 (CH2), 62.6 (CH2), 68.3 (CH), 71.2 (CH), 71.9 (CH), 72.6 (CH), 99.9 (CH2OCsuger), 110.2 (CAr), 110.3 (CAr), 125.1 (CHtriazole), 130.0 (CAr), 138.2 (CArNO2), 143.1 (CtriazoleCH2O), 144.2 (CArOCH3), 147.8 (CArOCH3), 169.3, 169.4, 170.1, 170. 6 (C=O). Elemental analysis, calc. (%) for C25H30N4O14: C 49.18, H 4.95, N 9.18; found: C 48.95, H 5.14, N 9.06.

3.1.8. (2R,3R,4S,5R)-2-((1-(2,5-dimethoxy-4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahydro-2H-py-ran-3,4,5-triyl triacetate (11)

The title compound was separated and purified by column chromatography (Petroleum ether/ethyl acetate 8/2) as a yellow solid (83%). Mp 142–143 °C. TLC (Petroleum ether/ethyl acetate 8/2) Rf = 0.34. FT-IR (KBr, νmax/cm−1): 1751 (C=O). 1H NMR (400 MHz, CDCl3): δ (ppm) = 2.00, 201 (ss, 6 H, 2 COCH3), 2.04 (s, 3 H, COCH3), 3.40–3.45 (m, 1 H, CHa), 3.98, 4.00 (ss, 6 H, 2 OCH3), 4.15–4.17 (m, 1 H, CHb), 4.68, 4.69 (ss, 1 H, CH), 4.84, 4.87 (ss, 1 H, CH), 5.01–4.93 (m, 3 H, CH2+CH), 5.16 (m, 1 H, CH), 7.67 (s, 1 H, ArH), 7.79 (s, 1 H, ArH), 8.33 (s, 1 H, ArHtriazole). 13C NMR (75 MHz, CDCl3): δ (ppm) = 20.6 (COCH3), 20.7 (COCH3), 56.9 (OCH3), 57.3 (OCH3), 62.1 (CH2), 62.2 (CH2), 68.8 (CH), 70.7 (CH), 71.2 (CH), 99.9 (CH2OCsuger), 110.1 (CAr), 110.3 (CAr), 125.0 (CHtriazole), 130.0 (CAr), 138.1 (CArNO2), 143.1 (CtriazoleCH2O), 144.3 (CArOCH3), 147.8 (CArOCH3), 169.4, 169.8, 170.0 (C=O). Elemental analysis, calc. (%) for C22H26N4O12: C 49. 07, H 4.87, N 10.41; found: C 49.32, H 5.13, N 10.59.

3.2. Biology

3.2.1. Preparation of Stock Solutions for Each Studied Designed Compound

Two hundred microliters of each of tested compound were completely solubilized in 300 µL of 10% dimethyl sulphoxide, and partly dissolved compounds were agitated under constant condition (150 RPM for 3 h at 35 °C) to a final concentration of 50 mg/mL. All dissolved compounds were kept in labeled and tightly closed sterile falcon tube.

3.2.2. Bacterial Cultures and Growth Conditions

A stock of four targeted problematic microbes, including Gram-negative species (Pseudomonas aeruginosa ATCC 10145), Gram-positive species (Staphylococcus aureus ATCC ATCC 43300), yeast (Candida albicans ATCC 10231), and mold (Aspergillus niger ATCC 6275), which was maintained at −20 °C, was initially proliferated and prepared according to the literature [73]. The numbers of targeted microbial cells were almost 106 CFU/mL. All experimental trials were repeated three times during different time spans.

3.2.3. Antimicrobial Activity Assay

Antimicrobial susceptibility testing of six tested compounds (5, 6, 7, 9, 10, and 11) and solvent was performed using both disc and well diffusion agar methods [74]. Concisely, a 100 µL of each microbial culture was carefully distributed onto the surface of Mueller-Hinton agar (MHA) plates using a sterile cotton swab. For disc-diffusion assay, saturated discs with each dissolved compound and one for DMSO solvent were placed on the surface of a MTA medium. While in case of the well diffusion assay, seven wells with 8 mm diameter were drilled into the bottom of a MHA medium under aseptic environments and filled with 100 μL of each tested compound and solvent. After that, all inoculated MHA plates were incubated overnight at 37 °C for bacterial species and 30 °C for fungal species. Distilled water served as negative controls while standard antibiotic discs of Ampicillin and Nystatin were used as the positive controls. The thicknesses of the clear zones around the discs and wells were estimated in mm after the optimum incubation period (24 h). The obtained results were recorded as the mean ± standard deviation.

3.2.4. Minimum Inhibitory Concentration (MIC)

The broth dilution assay was applied for determining the MIC values for each tested compound. From a stock solution of each tested compound (50 mg/mL), three different concentrations (2.5, 5, and 10 mg/mL) of each compound were transferred to a tube containing 20 µL of fresh pathogen microbial culture to estimate the lethal concentrations. After three different time intervals (5, 10, 15, and 20 min), the densities of surviving cells were counted using the plate count viability assay [75].

3.2.5. Estimation of Decay Rate Using Pseudo-First-Order Kinetic Modeling

Pseudo-first-order kinetic modeling was employed to calculate the decay rate (K1) for each target pathogen, establishing the number of microbial cells that were treated with a low concentration of each compound at different contact times (Nt) with respect to the original counts (N0) according to Equation (1) [76]:
log ( q e − q t ) = log q e − K 1 t 2.303
where K1 (1 min−1) is the rate of inactivation, qe (mg g−1), and qt (mg g−1) are the amounts sorbed at equilibrium and at time t (min), respectively. A straight line of ln (qe − qt) versus t suggests that this kinetic model applies to the data. For obtaining the relationship between the rate of decayed cells and exposure time, a linear regression (R2) was fulfilled.

3.2.6. Toxicity Valuation of the Tested Compounds

The toxicity proportion was measured using the Microtox® Model 500 (M500) analyzer (Modern Water Inc, New Castle, DE, USA) and cytotoxicity assay to exploit these compounds without hazardous effects on individuals or other living creatures in different biomedical applications [77].

3.2.7. Statistical Analyses

Statistical analysis was performed using the software version 5.0 (USA) of GraphPad Prism. Two-way analysis of variance (ANOVA) and Student’s t-test were accomplished to evaluate significance (p < 0.05) between the concentrations of tested compounds and log counts of viable cells of target microbes.

4. Conclusions

In summary, six novel 1,2,3-triazole glucosides were synthesized using the standard-click reactions of aryl azides 1 and 8 with sugars 2–4. The antibacterial activity of the new triazoles was evaluated against S. aureus and P. aeruginosa in comparison with “Ampicillin”, while the antifungal activity was assessed against C. albicans and A. niger relative to the reference drug “Nystatin”. The antimicrobial evaluation of the new 1,2,3-triazole glucosides revealed a potent activity of compound 5 in comparison with other tested compounds, which obviously highlighted the positive impact of the triethylene glycol sidearm and the acetylated sugar unit on the enhanced biological activity.

Supplementary Materials

The following are available online, Figure S1: 1H NMR spectrum of 1,2,3-triazole glucoside 5 (CDCl3, 400 MHz), Figure S2: 13C NMR spectrum of 1,2,3-triazole glucoside 5 (CDCl3, 100 MHz), Figure S3: 1H NMR spectrum of 1,2,3-triazole glucoside 6 (CDCl3, 400 MHz); Figure S4: 13C NMR spectrum of 1,2,3-triazole glucoside 6 (CDCl3, 100 MHz), Figure S5: 1H NMR spectrum of 1,2,3-triazole glucoside 7 (CDCl3, 400 MHz), Figure S6: 13C NMR spectrum of 1,2,3-triazole glucoside 7 (CDCl3, 100 MHz), Figure S7: 1H NMR spectrum of 1,2,3-triazole glucoside 9 (CDCl3, 400 MHz), Figure S8: 13C NMR spectrum of 1,2,3-triazole glucoside 9 (CDCl3, 100 MHz), Figure S9: 1H NMR spectrum of 1,2,3-triazole glucoside 10 (CDCl3, 400 MHz), Figure S10: 13C NMR spectrum of 1,2,3-triazole glucoside 10 (CDCl3, 100 MHz), Figure S11: 1H NMR spectrum of 1,2,3-triazole glucoside 11 (CDCl3, 400 MHz), Figure S12: 13C NMR spectrum of 1,2,3-triazole glucoside 11 (CDCl3, 100 MHz).

Author Contributions

The research group from the National Research Centre, Cairo, Egypt, including T.E.M., H.F.N. and W.A.E.-S. (Photochemistry Department, Chemical Industries Research Division) conceived the current research work, participated in the research steps, interpreted the results, discussed the experimental data, and prepared the manuscript. B.A.H. (Environmental Microbiology La., Water Pollution Research Department, Environmental Research Division, National Research Centre) conducted the in vitro biological assays, provided the experimental procedures, and results of the antimicrobial assay part. A.A.E.S. participated in the interpretation of results, discussion of the experimental data, the review process, and editing. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Thomas, C.M.; Nielsen, K.M. Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat. Rev. Microbiol. 2005, 3, 711–721. [Google Scholar] [CrossRef] [PubMed]
  2. von Wintersdorff, C.J.H.; Penders, J.; van Niekerk, J.M.; Mills, N.D.; Majumder, S.; van Alphen, L.B.; Savelkoul, P.H.M.; Wolffs, P.F.G. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Front. Microbiol. 2016, 7, 173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Ochman, H.; Lawrence, J.G.; Groisman, E.A. Lateral gene transfer and the nature of bacterial innovation. Nature 2000, 405, 299–304. [Google Scholar] [CrossRef] [PubMed]
  4. Malik, B.; Bhattacharyya, S. Antibiotic drug-resistance as a complex system driven by socio-economic growth and antibiotic misuse. Sci. Rep. 2019, 9, 9788. [Google Scholar] [CrossRef]
  5. Woodford, N.; Ellington, M.J. The emergence of antibiotic resistance by mutation. Clin. Microbiol. Infect. 2007, 13, 5–18. [Google Scholar] [CrossRef] [Green Version]
  6. Levy, S.B.; Bergman, M.M. The antibiotic paradox: How the misuse of antibiotics destroys their curative powers. In Clinical Infectious Diseases, 2nd ed.; Perseus Publishing: Boston, MA, USA, 2003. [Google Scholar]
  7. Llor, C.; Bjerrum, L. Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. Ther. Adv. Drug Saf. 2014, 5, 229–241. [Google Scholar] [CrossRef] [Green Version]
  8. Fuda, C.C.S.; Fisher, J.F.; Mobashery, S. β-Lactam resistance in Staphylococcus aureus: The adaptive resistance of a plastic genome. Cell. Mol. Life Sci. 2005, 62, 2617–2633. [Google Scholar] [CrossRef]
  9. Butler, M.S.; Hansford, K.A.; Blaskovich, M.A.T.; Halai, R.; Cooper, M.A. Glycopeptide antibiotics: Back to the future. J. Antibiot. 2014, 67, 631–644. [Google Scholar] [CrossRef]
  10. Garneau-Tsodikova, S.; Labby, K.J. Mechanisms of resistance to aminoglycoside antibiotics: Overview and perspectives. Med. Chem. Commun. 2016, 7, 11–27. [Google Scholar] [CrossRef] [Green Version]
  11. Gade, N.D.; Qazi, M.S. Fluoroquinolone therapy in Staphylococcus aureus infections: Where do we stand? J. Lab. Physicians 2013, 5, 109–112. [Google Scholar] [CrossRef]
  12. Singh, A.; Grover, S.; Sinha, S.; Das, M.; Somvanshi, P.; Grover, A. Mechanistic principles behind molecular mechanism of Rifampicin resistance in mutant RNA polymerase beta subunit of myco- bacterium tuberculosis. J. Cell. Biochem. 2017, 118, 4594–4606. [Google Scholar] [CrossRef] [PubMed]
  13. Cohen, K.A.; Manson, A.L.; Desjardins, C.A.; Abeel, T.; Earl, A.M. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: Progress, promise, and challenges. Genome Med. 2019, 11, 45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Palomino, J.C.; Martin, A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 2014, 3, 317–340. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Lee, C.-R.; Lee, J.H.; Park, M.; Park, K.S.; Bae, I.K.; Kim, Y.B.; Cha, C.-J.; Jeong, B.C.; Lee, S.H. Biology of acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front. Cell. Infect. Microbiol. 2017, 7, 55. [Google Scholar] [CrossRef] [Green Version]
  16. Singh, H.; Thangaraj, P.; Chakrabarti, A. Acinetobacter baumannii: A brief account of mechanisms of multidrug resistance and current and future therapeutic management. J. Clin. Diagn. Res. 2013, 7, 2602–2605. [Google Scholar] [CrossRef] [PubMed]
  17. Ciofu, O.; Tolker-Nielsen, T. Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents–How P. aeruginosa can escape antibiotics. Front. Microbiol. 2019, 10, 913. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Ashok, D.; Gundu, S.; Aamate, V.K.; Devulapally, M.G.; Bathini, R.; Manga, V. Dimers of coumarin-1,2,3-triazole hybrids bearing alkyl spacer: Design, microwave-assisted synthesis, molecular docking and evaluation as antimycobacterial and antimicrobial agents. J. Mol. Struct. 2018, 1157, 312–321. [Google Scholar] [CrossRef]
  19. Goud, G.L.; Ramesh, S.; Ashok, D.; Reddy, V.P.; Yogeeswari, P.; Sriram, D.; Saikrishna, B.; Manga, V. Design, synthesis, molecular-docking and antimycobacterial evaluation of some novel 1,2,3-triazolyl xanthenones. Med. Chem. Commun. 2017, 8, 559–570. [Google Scholar] [CrossRef]
  20. Ashok, D.; Chiranjeevi, P.; Kumar, A.V.; Sarasija, M.; Krishna, V.S.; Sriram, D.; Balasubramanian, S. 1,2,3-Triazole-fused spirochromenes as potential anti-tubercular agents: Synthesis and biological evaluation. RSC Adv. 2018, 8, 16997–17007. [Google Scholar] [CrossRef] [Green Version]
  21. Pogaku, V.; Krishna, V.S.; Balachandran, C.; Rangan, K.; Sriram, D.; Aoki, S.; Basavoju, S. The design and green synthesis of novel benzotriazoloquinolinyl spirooxindolopyrrolizidines: Antimycobacterial and antiproliferative studies. New J. Chem. 2019, 43, 17511–17520. [Google Scholar] [CrossRef]
  22. Phatak, P.S.; Bakale, R.D.; Dhumal, S.T.; Dahiwade, L.K.; Choudhari, P.B.; Krishna, V.S.; Sriram, D.; Haval, K.P. Synthesis, antitubercular evaluation and molecular docking studies of phthalimide bearing 1,2,3-triazoles. Synth. Commun. 2019, 49, 2017–2028. [Google Scholar] [CrossRef]
  23. Reddyrajula, R.; Dalimba, U.; Kumar, S.M. Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies. Eur. J. Med. Chem. 2019, 168, 263–282. [Google Scholar] [CrossRef] [PubMed]
  24. Sajja, Y.; Vanguru, S.; Vulupala, H.R.; Bantu, R.; Yogeswari, P.; Sriram, D.; Nagarapu, L. Design, synthesis and in vitro antituberculosis activity of benzo [6,7]cyclohepta [1–b]pyridine-1,2,3-triazole derivatives. Bioorg. Med. Chem. 2017, 27, 5119–5121. [Google Scholar] [CrossRef]
  25. Shaikh, M.H.; Subhedar, D.D.; Nawale, L.; Sarkar, D.; Khan, F.A.K.; Sangshettic, J.N.; Shingate, B.B. 1,2,3-Triazole derivatives as antitubercular agents: Synthesis, biological evaluation and molecular docking study. Med. Chem. Commun. 2015, 6, 1104–1116. [Google Scholar] [CrossRef]
  26. El Malah, T.; Nour, H.F.; Dehbi, O.; Abdel-Megeid, F.M.E.; Essam El-Din Mahmoud, A.; Ali, M.M.; Soliman, S.M. Click synthesis, anticancer activity and molecular docking studies on pyridazinone scaffolds. Curr. Org. Chem. 2018, 22, 2300–2307. [Google Scholar] [CrossRef]
  27. El Malah, T.; Nour, H.F.; Nayl, A.A.; Elkhashab, R.A.; Abdel-Megeid, F.M.E.; Ali, M.M. Anticancer evaluation of tris(triazolyl)triazine derivatives generated via click chemistry. Aust. J. Chem. 2016, 69, 905–910. [Google Scholar] [CrossRef]
  28. Huang, R.-Z.; Liang, G.-B.; Li, M.-S.; Fang, Y.-L.; Zhao, S.-F.; Zhou, M.-M.; Liao, Z.-X.; Sun, J.; Wang, H.-S. Synthesis and discovery of asiatic acid based 1,2,3-triazole derivatives as antitumor agents blocking NF-κB activation and cell migration. Med. Chem. Commun. 2019, 10, 584–597. [Google Scholar] [CrossRef]
  29. Ruddarraju, R.R.; Murugulla, A.C.; Kotla, R.; Tirumalasetty, M.C.B.; Wudayagiri, R.; Donthabakthuni, S.; Maroju, R. Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives. Med. Chem. Commun. 2017, 8, 176–183. [Google Scholar] [CrossRef]
  30. Khalil, H.; El Malah, T.; Abd El Maksoud, A.I.; El Halfawy, I.; El Rashedy, A.A.; El Hefnawy, M. Identification of novel and efficacious chemical compounds that disturb influenza A virus entry in vitro. Front. Cell. Infect. Microbiol. 2017, 7, 304. [Google Scholar] [CrossRef] [Green Version]
  31. Głowacka, I.E.; Andrei, G.; Schols, D.; Snoeck, R.; Piotrowska, D.G. Phosphonylated acyclic guanosine analogues with the 1,2,3-triazole linker. Molecules 2015, 20, 18789–18807. [Google Scholar] [CrossRef] [Green Version]
  32. Cheng, H.; Wan, J.; Lin, M.-I.; Liu, Y.; Lu, X.; Liu, J.; Xu, Y.; Chen, J.; Tu, Z.; Cheng, Y.-S.E.; et al. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. J. Med. Chem. 2012, 55, 2144–2153. [Google Scholar] [CrossRef]
  33. He, Y.-W.; Dong, C.-Z.; Zhao, J.-Y.; Ma, L.-L.; Li, Y.-H.; Aisa, H.A. 1,2,3-Triazole-containing derivatives of rupestonic acid: Click-chemical synthesis and antiviral activities against influenza viruses. Eur. J. Med. Chem. 2014, 76, 245–255. [Google Scholar] [CrossRef]
  34. Kaoukabi, H.; Kabri, Y.; Curti, C.; Taourirte, M.; Rodriguez-Ubis, J.C.; Snoeck, R.; Andrei, G.; Vanelle, P.; Lazrek, H.B. Dihydropyrimidinone/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV). Eur. J. Med. Chem. 2018, 155, 772–781. [Google Scholar] [CrossRef]
  35. Saeedi, M.; Mohammadi-Khanaposhtani, M.; Pourrabia, P.; Razzaghi, N.; Ghadimi, R.; Imanparast, S.; Faramarzi, M.A.; Bandarian, F.; Esfahani, E.N.; Safavi, M.; et al. Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new antidiabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study. Bioorg. Chem. 2019, 83, 161–169. [Google Scholar] [CrossRef] [PubMed]
  36. Avula, S.K.; Khan, A.; Rehman, N.U.; Anwar, M.U.; Al-Abri, Z.; Wadood, A.; Riaz, M.; Csuk, R.; Al-Harrasi, A. Synthesis of 1H-1,2,3-triazole derivatives as new α-glucosidase inhibitors and their molecular docking studies. Bioorg. Chem. 2018, 81, 98–106. [Google Scholar] [CrossRef] [PubMed]
  37. Ferreira, S.B.; Sodero, A.C.R.; Cardoso, M.F.C.; Lima, E.S.; Kaiser, C.R.; Silva, F.P., Jr.; Ferreira, V.F. Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as α-glucosidases inhibitors. J. Med. Chem. 2010, 53, 2364–2375. [Google Scholar] [CrossRef] [PubMed]
  38. da Rocha, D.R.; Santos, W.C.; Lima, E.S.; Ferreira, V.F. Synthesis of 1,2,3-triazole glycoconjugates as inhibitors of α-glucosidases. Carbohydr. Res. 2012, 350, 14–19. [Google Scholar] [CrossRef] [PubMed]
  39. Kaushik, C.P.; Luxmi, R.; Kumar, M.; Singh, D.; Kumar, K.; Pahwa, A. One-pot facile synthesis, crystal structure and antifungal activity of 1,2,3-triazoles bridged with amine-amide functionalities. Synth. Commun. 2019, 49, 118–128. [Google Scholar] [CrossRef]
  40. Dai, Z.-C.; Chen, Y.-F.; Zhang, M.; Li, S.-K.; Yang, T.-T.; Shen, L.; Wang, J.-X.; Qian, S.-S.; Zhue, H.-L.; Ye, Y.-H. Synthesis and antifungal activity of 1,2,3-triazole phenylhydrazone derivatives. Org. Biomol. Chem. 2015, 13, 477–486. [Google Scholar] [CrossRef]
  41. Akolkar, S.V.; Nagargoje, A.A.; Krishna, V.S.; Sriram, D.; Sangshetti, J.N.; Damaled, M.; Shingate, B.B. New N-phenylacetamide-incorporated 1,2,3-triazoles: [Et3NH][OAc]-mediated efficient synthesis and biological evaluation. RSC Adv. 2019, 9, 22080–22091. [Google Scholar] [CrossRef] [Green Version]
  42. Huo, X.-Y.; Guo, L.; Chen, X.-F.; Zhou, Y.-T.; Zhang, J.; Han, X.-Q.; Dai, B. Design, synthesis, and antifungal activity of novel aryl-1,2,3-triazole-β-carboline hybrids. Molecules 2018, 23, 1344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Mohammed, I.; Kummetha, I.R.; Singh, G.; Sharova, N.; Lichinchi, G.; Dang, J.; Stevenson, M.; Rana, T.M. 1,2,3-Triazoles as amide bioisosteres: Discovery of a new class of potent HIV-1 Vif antagonists. J. Med. Chem. 2016, 59, 7677–7682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Zhou, Z.; Liu, T.; Wu, G.; Kang, D.; Fu, Z.; Wang, Z.; De Clercq, E.; Pannecouque, C.; Zhan, P.; Liu, X. Targeting the hydrophobic channel of NNIBP: Discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Org. Biomol. Chem. 2019, 17, 3202–3321. [Google Scholar] [CrossRef] [PubMed]
  45. Jiang, X.; Wu, G.; Zalloum, W.A.; Meuser, M.E.; Dick, A.; Sun, L.; Chen, C.-H.; Kang, D.; Jing, L.; Jia, R.; et al. Discovery of novel 1,4-disubstituted 1,2,3-triazole phenyl- alanine derivatives as HIV-1 capsid inhibitors. RSC Adv. 2019, 9, 28961–28986. [Google Scholar] [CrossRef] [Green Version]
  46. da Silva, F.D.C.; de Souza, M.C.B.V.; Frugulhetti, I.I.P.; Castro, H.C.; Silmara, L.D.O.; de Souza, T.M.L.; Rodrigues, D.Q.; Souza, A.M.T.; Abreu, P.A.; Passamani, F.; et al. Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates. Eur. J. Med. Chem. 2009, 44, 373–383. [Google Scholar] [CrossRef]
  47. Rao, P.S.; Kurumurthy, C.; Veeraswamy, B.; Kumar, G.S.; Poornachandra, Y.; Kumar, C.G.; Vasamsetti, S.B.; Kotamraju, S.; Narsaiah, B. Synthesis of novel 1,2,3-triazole substituted-N-alkyl/aryl nitrone derivatives, their anti-inflammatory and anticancer activity. Eur. J. Med. Chem. 2014, 80, 184–191. [Google Scholar]
  48. Naaz, F.; Pallavi, M.C.P.; Shafic, S.; Mulakayala, N.; Yar, M.S.; Kumar, H.M.S. 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & antiinflammatory activity. Bioorg. Chem. 2018, 81, 1–20. [Google Scholar]
  49. Haider, S.; Alam, M.S.; Hamid, H.; Shafi, S.; Nargotra, A.; Mahajan, P.; Nazreen, S.; Kalle, A.M.; Kharbanda, C.; Ali, Y.; et al. Synthesis of novel 1,2,3-triazole based benzoxazolinones: Their TNF-α based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation. Eur. J. Med. Chem. 2013, 70, 579–588. [Google Scholar] [CrossRef]
  50. Ahmadi, F.; Ghayahbashi, M.R.; Sharifzadeh, M.; Alipoiur, E.; Ostad, S.N.; Vosooghi, M.; Khademi, H.R.; Amini, M. Synthesis and evaluation of anti-inflammatory and analgesic activities of new 1,2,4-triazole derivatives. Med. Chem. 2015, 11, 69–76. [Google Scholar] [CrossRef]
  51. Chu, X.-M.; Wang, C.; Wang, W.-L.; Liang, L.-L.; Liu, W.; Gong, K.-K.; Sun, K.-L. Triazole derivatives and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem. 2019, 166, 206–223. [Google Scholar] [CrossRef]
  52. Batra, N.; Rajendran, V.; Agarwal, D.; Wadi, I.; Ghosh, P.C.; Gupta, R.D.; Nath, M. Synthesis and antimalarial evaluation of [1,2,3]-triazole-tethered sulfonamide-berberine hybrids. ChemistrySelect 2018, 3, 9790–9793. [Google Scholar] [CrossRef]
  53. Porta, E.O.J.; Verdaguer, I.B.; Perez, C.; Banchio, C.; Ferreira de Azevedo, M.; Katzin, A.M.; Labadie, G.R. Repositioning Salirasib as a new antimalarial agent. Med. Chem. Commun. 2019, 10, 1599–1605. [Google Scholar] [CrossRef] [PubMed]
  54. Kaushik, C.P.; Pahwa, A. Convenient synthesis, antimalarial and antimicrobial potential of thioethereal 1,4-disubstituted 1,2,3-triazoles with ester functionality. Med. Chem. Res. 2018, 27, 458–469. [Google Scholar] [CrossRef]
  55. Ashok, D.; Gundu, S.; Aamate, V.K.; Devulapally, M.G. Microwave-assisted synthesis, antioxidant and antimicrobial evaluation of 2-indolinone-based bis-1,2,3-triazole derivatives. Mol. Divers. 2018, 22, 57–70. [Google Scholar] [CrossRef]
  56. Savegnago, L.; do Sacramento, M.; Brod, L.M.P.; Fronza, M.G.; Seus, N.; Lenardão, E.J.; Paixão, M.W.; Alves, D. Phenylselanyl-1H-1,2,3-triazole-4-carbonitriles: Synthesis, antioxidant properties and use as precursors to highly functionalized tetrazoles. RSC Adv. 2016, 6, 8021–8031. [Google Scholar] [CrossRef]
  57. Settypalli, T.; Chunduri, V.R.; Maddineni, A.K.; Begari, N.; Allagadda, R.; Kotha, P.; Chippada, A.R. Design, synthesis, in silico docking studies and biological evaluation of novel quinoxalinehydrazide hydrazone-1,2,3-triazole hybrids as α-glucosidase inhibitors and antioxidants. New J. Chem. 2019, 43, 15435–15452. [Google Scholar] [CrossRef]
  58. Saraei, M.; Ghasemi, Z.; Dehghan, G.; Hormati, M.; Ojaghi, K. Synthesis of some novel 1,2,3-triazole derivatives containing kojic acid moiety and evaluation for their antioxidant activity. Mon. Chem. 2017, 148, 917–923. [Google Scholar] [CrossRef]
  59. Singh, K.; Gangrade, A.; Jana, A.; Mandal, B.B.; Das, N. Design, synthesis, characterization, and anti- proliferative activity of organoplatinum compounds bearing a 1,2,3-triazole ring. ACS Omega 2019, 4, 835–841. [Google Scholar] [CrossRef]
  60. Kapkoti, D.S.; Singh, S.; Luqman, S.; Bhakuni, R.S. Synthesis of novel 1,2,3-triazole based artemisinin derivatives and their antiproliferative activity. New J. Chem. 2018, 42, 5978–5995. [Google Scholar] [CrossRef]
  61. Singh, A.; Saha, S.T.; Perumal, S.; Kaur, M.; Kumar, V. Azide-alkyne cycloaddition en route to 1H- 1,2,3-triazole-tethered isatin-ferrocene, ferrocenylmethoxy-isatin, and isatin-ferrocenylchalcone conjugates: Synthesis and antiproliferative evaluation. ACS Omega 2018, 3, 1263–1268. [Google Scholar] [CrossRef] [Green Version]
  62. Fu, D.-J.; Zhang, S.-Y.; Liu, Y.-C.; Yue, X.-X.; Liu, J.-J.; Song, J.; Zhao, R.-H.; Li, F.; Sun, H.-H.; Zhang, Y.-B.; et al. Design, synthesis and antiproliferative activity studies of 1,2,3-triazole-chalcones. Med. Chem. Commun. 2016, 7, 1664–1671. [Google Scholar] [CrossRef]
  63. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise Huisgen cycloaddition process: Copper(I)-catalyzed regioselective “Ligation” of azides and terminal alkynes. Angew. Chem. Int. Ed. 2002, 41, 2596–2599. [Google Scholar] [CrossRef]
  64. Tornøe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase:  [1,2,3]-Triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057–3064. [Google Scholar] [CrossRef]
  65. Ay, K.; Ispartaloğlu, B.; Halay, E.; Ay, E.; Yaşa, İ.; Karayıldırım, T. Synthesis and antimicrobial evaluation of sulfanilamide- and carbohydrate-derived 1,4-disubstitued-1,2,3-triazoles via click chemistry. Med. Chem. Res. 2017, 26, 1497–1505. [Google Scholar] [CrossRef]
  66. Agalave, S.G.; Maujan, S.R.; Pore, V.S. Click chemistry: 1,2,3-Triazoles as pharmacophores. Chem. Asian J. 2011, 6, 2696–2718. [Google Scholar] [CrossRef]
  67. Alminderej, F.M.; Elganzory, H.H.; El-Bayaa, M.N.; Awad, H.M.; El-Sayed, W.A. Synthesis and cytotoxic activity of new 1,3,4-thiadiazole thioglycosides and 1,2,3-triazolyl-1,3,4-thiadiazole N-glycosides. Molecules 2019, 24, 3738. [Google Scholar] [CrossRef] [Green Version]
  68. El-Sayed, W.A.; Abdel-Rahman, A.A.-H. Copper-catalyzed synthesis and antimicrobial activity of disubstituted 1,2,3-triazoles starting from 1-propargyluracils and ethyl (4-azido-1,2,3-trihydroxy- butyl)furan-3-carboxylate. Z. Naturforsch B. 2010, 65, 57–66. [Google Scholar] [CrossRef]
  69. Tolan, H.E.M.; El-Sayed, W.A.; Tawfek, N.; Abdel-Megeid, F.M.E.; Kutkat, O.M. Synthesis and anti-H5N1 virus activity of triazole- and oxadiazole-pyrimidine hybrids and their nucleoside analogs. Nucleosides Nucleotides Nucleic Acids 2019. [Google Scholar] [CrossRef]
  70. Kassem, A.F.; Abbas, E.M.H.; El-Kady, D.S.; Awad, H.M.; El-Sayed, W.A. Synthesis, docking studies and anticancer activity of new tetrazolyl- and (triazolyl)thiazole glycosides and acyclic analogs. Mini-Rev. Med. Chem. 2019, 19, 933–948. [Google Scholar] [CrossRef]
  71. El-Sayed, W.A.; Khalaf, H.S.; Mohamed, S.F.; Hssien, H.A.; Kutkat, O.M.; Amr, A.-E.E. Synthesis and antiviral activity of 1,2,3-triazole glycosides based substituted pyridine via click cycloaddition. Russ. J. Gen. Chem. 2017, 87, 2444–2453. [Google Scholar] [CrossRef]
  72. Elkanzia, N.A.A.; El-Sofany, W.I.; Gaballah, S.T.; Mohamed, A.M.; Kutkat, O.; El-Sayed, W.A. Synthesis, molecular modeling, and antiviral activity of novel triazole nucleosides and their analogs. Russ. J. Gen. Chem. 2019, 89, 1896–1904. [Google Scholar] [CrossRef]
  73. Elbatanony, M.M.; El-Feky, A.M.; Hemdan, B.A.; El-Liethy, M.A. Assessment of the antimicrobial activity of the lipoidal and pigment extracts of Punica granatum L. leaves. Acta Ecol. Sin. 2019, 39, 89–94. [Google Scholar] [CrossRef]
  74. APHA. Standard Methods for the Examination of Water and Wastewater, 22nd ed.; American Public Health Association/American Water Works Association/Water Environment Federation: Washington, DC, USA, 2012. [Google Scholar]
  75. El Nahrawy, A.M.; Abou Hammad, A.B.; Bakr, A.M.; Hemdan, B.A.; Wassel, A.R. Decontamination of ubiquitous harmful microbial lineages in water using an innovative Zn2Ti0.8Fe0.2O4 nanostructure: Dielectric and terahertz properties. Heliyon 2019, 5, e02501. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Ali, G.W.; El-Hotaby, W.; Hemdan, B.; Abdel-Fattah, W.I. Thermosensitive chitosan/phosphate hydrogel-composites fortified with Ag versus Ag@Pd for biomedical applications. Life Sci. 2018, 194, 185–195. [Google Scholar] [CrossRef]
  77. Flokstra, B.R.; Aken, B.V.; Shcnoor, J.L. Microtox® toxicity test: Detoxification of TNT and RDX contaminated solutions by poplar tissue cultures. Chemospher 2008, 71, 1970–1976. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 25 00790 g001 550
Figure 1. Chemical structures of pharmaceutical drugs containing 1,2,3-triazole rings.
Figure 1. Chemical structures of pharmaceutical drugs containing 1,2,3-triazole rings.
Molecules 25 00790 g001
Molecules 25 00790 sch001 550
Scheme 1. Click synthesis of 1,2,3-triazole glucosides 5–7.
Scheme 1. Click synthesis of 1,2,3-triazole glucosides 5–7.
Molecules 25 00790 sch001
Molecules 25 00790 sch002 550
Scheme 2. Click synthesis of 1,2,3-triazole glucosides 9–11.
Scheme 2. Click synthesis of 1,2,3-triazole glucosides 9–11.
Molecules 25 00790 sch002
Molecules 25 00790 g002 550
Figure 2. Minimum inhibitory concentration values of the tested compounds (a) 5, (b) 6, and (c) 7 towards targeted microbes. The remained viable cell populations at various time intervals of 5, 10, and 15 min, are also shown. Two-way analysis of variance (ANOVA) states * indicates low correlation (p ≤ 0.05), ** indicates moderate correlation (p ≤ 0.01), *** indicates high correlation (p ≤ 0.001).
Figure 2. Minimum inhibitory concentration values of the tested compounds (a) 5, (b) 6, and (c) 7 towards targeted microbes. The remained viable cell populations at various time intervals of 5, 10, and 15 min, are also shown. Two-way analysis of variance (ANOVA) states * indicates low correlation (p ≤ 0.05), ** indicates moderate correlation (p ≤ 0.01), *** indicates high correlation (p ≤ 0.001).
Molecules 25 00790 g002
Molecules 25 00790 g003 550
Figure 3. Minimum inhibitory concentration values of the tested compounds (a) 9, (b) 10, and (c) 11 towards targeted microbes. The remained viable cell populations at various time intervals of 5, 10, and 15 min, are also shown. Two-way analysis of variance (ANOVA) states * indicates low correlation (p ≤ 0.05), ** indicates moderate correlation (p ≤ 0.01), *** indicates high correlation (p ≤ 0.001).
Figure 3. Minimum inhibitory concentration values of the tested compounds (a) 9, (b) 10, and (c) 11 towards targeted microbes. The remained viable cell populations at various time intervals of 5, 10, and 15 min, are also shown. Two-way analysis of variance (ANOVA) states * indicates low correlation (p ≤ 0.05), ** indicates moderate correlation (p ≤ 0.01), *** indicates high correlation (p ≤ 0.001).
Molecules 25 00790 g003
Table
Table 1. The diameters of the inhibition zone of the tested compounds around tested pathogenic microbes.
Table 1. The diameters of the inhibition zone of the tested compounds around tested pathogenic microbes.
Tested CompoundsDiffusion AssaysInhibition Zone Diameters (mm)
S. aureusP. aeruginosaC. albicansA. niger
5Disc21 ± 0.2517 ± 0.2115 ± 0.2214 ± 0.25
Well25 ± 0.1519 ± 0.3217 ± 0.1516 ± 0.18
6Disc10 ± 0.238 ± 0.257 ± 0.236 ± 0.15
Well12 ± 0.2110 ± 0.279 ± 0.178 ± 0.24
7Disc13 ± 0.1110 ± 0.218 ± 0.269 ± 0.22
Well16 ± 0.2313 ± 0.2410 ± 0.1811 ± 0.27
9Disc14 ± 0.2810 ± 0.158 ± 0.189 ± 0.24
Well16 ± 0.1912 ± 0.3110 ± 0.2610 ± 0.29
10Disc16 ± 0.2812 ± 0.1511 ± 0.1810 ± 0.24
Well19 ± 0.2116 ± 0.3113 ± 0.2612 ± 0.29
11Disc18 ± 0.2315 ± 0.1113 ± 0.3111 ± 0.17
Well21 ± 0.1818 ± 0.2716 ± 0.2814 ± 0.21
AmpicillinDisc22 ± 0.2318 ± 0.2300
Well24 ± 0.1920 ± 0.1900
NystatinDisc0019 ± 0.1514 ± 0.21
Well0022 ± 0.2016 ± 0.23
Data values are presented as mean + SD (n = 3).
Table
Table 2. Summaries of the estimated values of minimum inhibitory concentration (MIC) for the tested compounds towards targeted microbes.
Table 2. Summaries of the estimated values of minimum inhibitory concentration (MIC) for the tested compounds towards targeted microbes.
Studied Designed CompoundsTargeted MicrobesEstimated Values of MIC in mg/mL
Concentration (mg/mL)Contact Time (min)
5S. aureus510
P. aeruginosa515
C. albicans1010
A. niger1010
6S. aureus1010
P. aeruginosa1015
C. albicans10>15
A. niger10>15
7S. aureus1010
P. aeruginosa1015
C. albicans1015
A. niger1015
9S. aureus105
P. aeruginosa1010
C. albicans1015
A. niger1015
10S. aureus515
P. aeruginosa1010
C. albicans1015
A. niger1015
11S. aureus515
P. aeruginosa1010
C. albicans1015
A. niger1015
AmpicillinS. aureus2.510
P. aeruginosa510
C. albicans>10>15
A. niger>10>15
NystatinS. aureus>10>15
P. aeruginosa>10>15
C. albicans2.515
A. niger515
Table
Table 3. The values of Microtox® EC50 percent concentrations of all studied designed compounds.
Table 3. The values of Microtox® EC50 percent concentrations of all studied designed compounds.
Studied CompoundsEC50% ConcentrationsEC50% DegreeToxicity Level
52040–19Extremely toxic
632020–39Very toxic
724540–59Toxic
928560–79Moderately toxic
10195≥100Nontoxic and safe
11232
Ampicillin292
Nystatin254
Table
Table 4. The killing rate of targeted microbes by 2.5 mg/mL of the designed compounds using Pseudo-first-order kinetic modeling.
Table 4. The killing rate of targeted microbes by 2.5 mg/mL of the designed compounds using Pseudo-first-order kinetic modeling.
Studied Designed CompoundsTargeted MicrobesKinetic Modeling
K1 (min−1)R2
5S. aureus0.09180.9983
P. aeruginosa0.07430.9912
C. albicans0.06570.9818
A. niger0.06130.9824
6S. aureus0.04120.9947
P. aeruginosa0.02150.9915
C. albicans0.02010.9832
A. niger0.01980.9872
7S. aureus0.05150.9963
P. aeruginosa0.02690.9950
C. albicans0.03150.9867
A. niger0.03420.9836
9S. aureus0.05580.9737
P. aeruginosa0.02470.9931
C. albicans0.03790.9812
A. niger0.03540.9841
10S. aureus0.08160.9912
P. aeruginosa0.06860.9894
C. albicans0.05480.9881
A. niger0.05260.9862
11S. aureus0.08450.9986
P. aeruginosa0.06760.9927
C. albicans0.05930.9880
A. niger0.05170.9832

Share and Cite

MDPI and ACS Style

El Malah, T.; Nour, H.F.; Satti, A.A.E.; Hemdan, B.A.; El-Sayed, W.A. Design, Synthesis, and Antimicrobial Activities of 1,2,3-Triazole Glycoside Clickamers. Molecules 2020, 25, 790. https://doi.org/10.3390/molecules25040790

AMA Style

El Malah T, Nour HF, Satti AAE, Hemdan BA, El-Sayed WA. Design, Synthesis, and Antimicrobial Activities of 1,2,3-Triazole Glycoside Clickamers. Molecules. 2020; 25(4):790. https://doi.org/10.3390/molecules25040790

Chicago/Turabian Style

El Malah, Tamer, Hany F. Nour, Amira A. E. Satti, Bahaa A. Hemdan, and Wael A. El-Sayed. 2020. "Design, Synthesis, and Antimicrobial Activities of 1,2,3-Triazole Glycoside Clickamers" Molecules 25, no. 4: 790. https://doi.org/10.3390/molecules25040790

APA Style

El Malah, T., Nour, H. F., Satti, A. A. E., Hemdan, B. A., & El-Sayed, W. A. (2020). Design, Synthesis, and Antimicrobial Activities of 1,2,3-Triazole Glycoside Clickamers. Molecules, 25(4), 790. https://doi.org/10.3390/molecules25040790

Article Metrics

Back to TopTop